European Archives - Page 269 of 1060 - European Medical Journal

Understanding Type 1 Diabetes: From Immunology to Treatment

This week’s episode discusses the immunology of Type 1 diabetes, and efforts to improve diagnosis and monitoring through screening programs and clinical trials.

Sickle Cell Thalassaemia and Overlapping Syndrome

Sickle cell disease (SCD) is a genetic condition caused by mutations in the haemoglobin (Hb) gene, resulting in various complications. One…

Review of the European Association for Haemophilia and Allied Disorders (EAHAD) Annual Congress 2024

The congress featured an enthusiastic welcome from 2024 EAHAD Congress President, Wolfgang Miesbach, who discussed the ongoing innovation…

Optimising Outcomes of Haemophilia Treatment

The 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) took place in Frankfurt, Germany, from…

EAHAD 2024 - Key Reflections from the Congress President

Live from EAHAD 2024, Wolfgang Miesbach, Congress President, shares a glimpse of the event, emphasises stand-out sessions from the…

Artificial Intelligence Could Identify Risk of Sexually Transmitted Infections

A new artificial intelligence tool, called ‘MySTIRisk’, has successfully determined infection risk scores for HIV, syphilis, gonorrhoea, and chlamydia. Read more.

Navigating Adjuvant Melanoma Treatment Choices

Navigating Adjuvant Melanoma Treatment Choices – The typical patient for whom adjuvant therapy may be considered, and provide details on…

Should Coronary Artery Fistula Be Treated?

Coronary artery fistulas (CAF) are communications between a coronary artery and a major vessel or a cardiac chamber.1 More than 90% of…

Contraceptive Use Among Females with HIV

HIV is an epidemic in Kenya. Females living with HIV (FLHIV) have an eight-fold increased risk of a pregnancy-related death compared to…

Early Breast Cancer Screening Reduces Mortality Risk

New research suggests that annual breast cancer screening starting at age 40 years, and continuing to age 79 or older, results in the highest reduction in mortality with minimal risks.